Saltar al contenido
República del Perú · Observatorio de la producción científica universitaria
OApol.org Observatorio de Inteligencia Científica Universitaria del Perú
OApol.org
Inicio Universidades Publicaciones Investigadores
Repositorios
Tesis y trabajos académicosRevistas
Indicadores
Ranking trimestralRanking por carreraObjetivos de Desarrollo SostenibleReporte OCDERed neuronal 3D
Acerca
MetodologíaPrivacidad

Inconsistent Reporting of Interactions Between Warfarin and Medicinal Plants Across Clinical Decision Support Resources

Uribe-Cavero L.J.; Vera-Maccha P.J.; Siguas-Huasasquiche A.; Bohorquez-Espino E.E.; Taype-Rondan A. · Journal of Evidence-Based Integrative Medicine (2025) · DOI: 10.1177/2515690x251334445

Resumen

Background: Warfarin, a commonly used anticoagulant, interacts with medicinal plants, potentially complicating patient management. Clinical Decision Resources (CDRs) provide guidance on these interactions, but inconsistencies across resources may impact clinical decisions. This study aims to evaluate the consistency of interaction reports between warfarin and medicinal plants across four online CDRs. Methods: A cross-sectional study was conducted. Medicinal plants assessed were selected from the World Health Organization's Phytotherapy Manual. Interaction reports were manually reviewed across four CDRs: UpToDate, ClinicalKey, DynaMed, and DrugBank. Interactions were categorized by severity as mild, moderate or severe. Results: Of 141 medicinal plants reviewed, 28 were documented as interacting with warfarin in at least one of the four assessed CDRs. DynaMed reported interactions for 18 plants, ClinicalKey for 15, UpToDate for 13, and DrugBank for 3. Only one plant (Ginseng - Panax ginseng) was consistently identified across all CDRs, although discrepancies in the direction of the interaction (whether it increased or decreased anticoagulant effect) were observed. Regarding interaction severity classifications, there was substantial variability, with ClinicalKey identifying the highest proportion of severe interactions (32.1%). Conclusion: We identified significant variability among CDRs in reporting interactions between warfarin and medicinal plants, which may lead to inconsistencies in clinical decision-making. To ensure more consistent and reliable patient care, standardized and comprehensive methodologies for assessing these interactions are needed. © The Author(s) 2025.

Instituciones: Universidad Nacional San Luis Gonzaga; Universidad San Ignacio de Loyola